ライフサイエンスコーパス: chemoprevention

1 nd nutrition counseling, risk reduction, and chemoprevention).

2 be used to test therapeutic agents aimed at chemoprevention.

3 rgets for pancreatic cancer treatment and/or chemoprevention.

4 been proven to be an effective strategy for chemoprevention.

5 se the model for studies on pathogenesis and chemoprevention.

6 aluation elucidate their role in dietary CRC chemoprevention.

7 , and better characterized kaempferol toward chemoprevention.

8 ctiveness of antioxidants in prostate cancer chemoprevention.

9 iotic electrophiles is a strategy for cancer chemoprevention.

10 nesis and could serve as a unique target for chemoprevention.

11 is known about decisions of women regarding chemoprevention.

12 urcumin as a novel approach to breast cancer chemoprevention.

13 ke tamoxifen or raloxifene for breast cancer chemoprevention.

14 lped in defining the crucial role of NRF2 in chemoprevention.

15 luding use of ACTs for malaria treatment and chemoprevention.

16 han their conventional NSAID counterparts in chemoprevention.

17 ons on the use of 5-ARIs for prostate cancer chemoprevention.

18 nanotechnology for enhancing the outcome of chemoprevention.

19 tase inhibitors (5-ARIs) for prostate cancer chemoprevention.

20 n botanic medicines for CTC-based metastatic chemoprevention.

21 s of compounds may have other effects beyond chemoprevention.

22 ing agents are in clinical trials for cancer chemoprevention.

23 on of this pathway is a potential target for chemoprevention.

24 ld affect strategies for early detection and chemoprevention.

25 vation of p53-dependent apoptosis during its chemoprevention.

26 c HBEC cells, suggesting their potential for chemoprevention.

27 may comprise targets for early treatment and chemoprevention.

28 it polyphenols have the potential for cancer chemoprevention.

29 E plays in photo-protection and skin cancer chemoprevention.

30 their potential use in cancer treatment and chemoprevention.

31 ning and should provide novel approaches for chemoprevention.

32 ugs (NSAIDs), and statins may play a role in chemoprevention.

33 tential utility of this natural compound for chemoprevention.

34 e markers as well as therapeutic targets for chemoprevention.

35 n the increasingly important field of cancer chemoprevention.

36 eillance with (n = 173) or without (n = 831) chemoprevention.

37 rker of gastric cancer risk and a target for chemoprevention.

38 the promising targets for cancer metastasis chemoprevention.

39 adherent children and those randomized to no chemoprevention.

40 children randomized to chemoprevention or no chemoprevention.

41 otechnology to improve the outcome of cancer chemoprevention.

42 ce was significantly reduced in women taking chemoprevention (10-year cumulative risk: 7% with chemop

43 prevention (10-year cumulative risk: 7% with chemoprevention; 21% with no chemoprevention; P < .001).

44 revention must be re-evaluated and uptake of chemoprevention actively encouraged.

45 lmethane (DIM) has been known to have cancer chemoprevention activity.

46 toms may improve QOL and potentially improve chemoprevention adherence.

47 ith a strong rationale to use this agent for chemoprevention against DCIS.

48 ith a strong rationale to use this agent for chemoprevention against DCIS.Oncogene advance online pub

49 ents, and a systematic step-wise approach to chemoprevention agent development are all critical for m

50 ancer Institute's Phase I/II prostate cancer chemoprevention agent development program.

51 inally, 3,3'-Diindolylmethane (DIM), a known chemoprevention agent, is capable of suppressing PCGEM1

52 emerging field of cancer prevention through chemoprevention agents and cancer vaccines offers signif

53 and antitumor activities or can function as chemoprevention agents by preventing the metabolic activ

54 ng assay permits identification of potential chemoprevention agents in complex natural product mixtur

55 demonstrated to facilitate the discovery of chemoprevention agents in complex natural product mixtur

56 ped to facilitate the discovery of potential chemoprevention agents that bind to human RXRalpha.

57 Six chemoprevention agents were identified: tamoxifen, ralox

58 lanoma, and to discuss new data on candidate chemoprevention agents, as chemoprevention has been sugg

59 BRCA1 gene tend to lack targets for approved chemoprevention agents.

60 xamining active metabolites, and considering chemoprevention all translated through clinical trials t

61 ported to display strong efficacy for cancer chemoprevention, although their mechanism of action is p

62 Topical tretinoin has been used for KC chemoprevention, although this use is unproven.

63 ders are encouraged to discuss the option of chemoprevention among women at increased BC risk.

64 RXRs represent important targets for cancer chemoprevention, an ultrafiltration mass spectrometry-ba

65 hibitors are being used increasingly in both chemoprevention and adjuvant settings.

66 ase public awareness about the importance of chemoprevention and cancer preventive vaccines.

67 UGT genetic polymorphisms in carcinogenesis, chemoprevention and cancer risk.

68 rationale for targeting acetylated STAT3 for chemoprevention and cancer therapy.

69 uggest that TBE-31 should also be tested for chemoprevention and chemotherapy in relevant models of c

70 s in the development of Nrf2-based drugs for chemoprevention and chemotherapy.

71 nhibition of NOTCH signaling may improve CRC chemoprevention and chemotherapy.

72 be a target for overcoming the resistance to chemoprevention and chemotherapy.

73 years, providing a window of opportunity for chemoprevention and early intervention.

74 utic target for both squamous cell carcinoma chemoprevention and for the treatment of established tum

75 approved drug in the clinic for colon cancer chemoprevention and has been tested for its chemoprevent

76 o investigate the mechanisms of prostacyclin chemoprevention and identify biomarkers for its use, we

77 l evaluation in deciding whether to initiate chemoprevention and in comparing the benefits and risks

78 taII is an important target for colon cancer chemoprevention and the PKCbeta-selective inhibitor enza

79 hways associated with ZEB1 are potential EMT chemoprevention and therapeutic targets in NSCLC.

80 at CDK2 is a useful molecular target for the chemoprevention and therapy against skin cancer.

81 at we believe to be a novel approach for CRC chemoprevention and therapy by increasing tumor glucocor

82 may be an important novel target for cancer chemoprevention and therapy by natural and synthetic ITC

83 ion opens up new opportunities for molecular chemoprevention and therapy of skin cancer by targeting

84 R), a synthetic retinoid effective in cancer chemoprevention and therapy, is thought to act via apopt

85 ticles is a promising new approach to cancer chemoprevention and therapy.

86 is element is a promising strategy of cancer chemoprevention and therapy.

87 SAMe and MTA may be attractive agents in the chemoprevention and treatment of colon cancer.

88 resent a suitable therapeutic option for the chemoprevention and treatment of Cowden disease patients

89 ective and safe therapeutic approach for the chemoprevention and treatment of human cholangiocarcinom

90 tracts have significant implications for the chemoprevention and treatment of prostate cancer and oth

91 Vitamin D is a well-studied agent for cancer chemoprevention and treatment.

92 tality, and currently, there is no effective chemoprevention and treatment.

93 arcinoma cell growth and may be targeted for chemoprevention and treatment.

94 genetic models promise to reduce the risk of chemoprevention and ultimately to reduce the risk and bu

95 ly induced, making them ideal candidates for chemoprevention and/or chemotherapy in these cancers.

96 rs, suggesting a new target for liver cancer chemoprevention and/or chemotherapy.

97 s, is a strategy for cancer chemotherapy and chemoprevention, and 3-amino-6-(3'-aminopropyl)-5H-inden

98 s RP, and RP alone cannot be recommended for chemoprevention, and new, better agents are needed in th

99 r using selective COX-2 inhibitors in cancer chemoprevention, and outline new avenues of research int

100 to strengthen the rationale for combination chemoprevention, and review plans for a clinical trial t

101 ered survey, with updated items on genetics, chemoprevention, and survivorship, was mailed to a strat

102 women choosing surveillance, with or without chemoprevention, and those undergoing bilateral prophyla

103 pulation level, to clear infections, provide chemoprevention, and to reduce onward transmission of in

104 Who are the best candidates for finasteride chemoprevention, and what are the clinical implications

105 cidal nets and expansion of seasonal malaria chemoprevention; and a reduction in coverage to 2006-08

106 me these challenges, here we developed a new chemoprevention approach that specifically targets prema

107 The key principles of cancer chemoprevention are discussed and areas for improvement

108 Clinical trials for chemoprevention are involving more diverse regimens, fol

109 pirin in pain-relief, cardio-protection, and chemoprevention are well-known to result from the covale

110 rvention, the incidence of malaria in the no chemoprevention arm was 6.95 episodes per person-year at

111 hese studies have important implications for chemoprevention as well as therapy of common, mutant p53

112 levels while being effective in the in vivo chemoprevention assay.

113 emerged as the most likely NSAID for use in chemoprevention because of its known cardiovascular bene

114 Prostate cancer is an attractive target for chemoprevention because of its ubiquity, treatment-relat

115 Selenium chemoprevention by apoptosis has been well studied, but

116 esis may be an important mechanism in cancer chemoprevention by PEITC.

117 lly selective approach for colorectal cancer chemoprevention by targeting APC-deficient cells for apo

118 bserved 8 months later, suggesting potential chemoprevention by targeting CCN1-inhibitable EGFR-depen

119 nic widely used in breast cancer therapy and chemoprevention), by the immobilized enzyme.

120 In the year after the cessation of chemoprevention, children who were highly adherent to DP

121 ative studies involving patients enrolled in chemoprevention clinical trials, including chromosomal a

122 ker is now being prospectively integrated in chemoprevention clinical trials.

123 netics, risk modeling, molecular targets for chemoprevention, clinical prevention trials, behavioral

124 ria exposure, and lower in those adherent to chemoprevention compared to nonadherent children and tho

125 information about hypothetical breast cancer chemoprevention decisions (mean uptake rate, 24.7%) and

126 However, the optimal chemoprevention drug and dosing strategy is unclear in a

127 Moreover, chemoprevention during early childhood prevented the dev

128 Despite great interest in cancer chemoprevention, effective agents are few.

129 The chemoprevention effects of ursodeoxycholic acid on color

130 of naturally occurring compounds with cancer chemoprevention effects that have become clinically avai

131 e establishing a new paradigm, combinatorial chemoprevention efficacy in familial adenomatous polypos

132 Chemoprevention, especially through the use of naturally

133 llocatechin-3-gallate (EGCG) is a well-known chemoprevention factor.

134 ve been the focus of research in the dietary/chemoprevention field.

135 ), widely used for adjuvant chemotherapy and chemoprevention for breast cancer, increases a risk of d

136 The concept of chemoprevention for the explicit benefit of the canine i

137 le support for the use of analgesic drugs as chemoprevention for this disease.

138 In this setting, effective antimalarial chemoprevention fostered the development of CD4(+) T cel

139 data on candidate chemoprevention agents, as chemoprevention has been suggested as an unexplored appr

140 Cancer chemoprevention has many challenges to face but this onl

141 ement of duodenal neoplasia is difficult and chemoprevention has not been successful.

142 Despite significant progress, chemoprevention has not been widely adopted.

143 Our data suggest that seasonal malaria chemoprevention has the potential to avert several milli

144 molecular targets for effective colon cancer chemoprevention have been characterized and validated.

145 y potential targets for molecularly targeted chemoprevention, here we perform integrated cross-specie

146 breast cancer incidence in women opting for chemoprevention highlights the potential for risk reduct

147 t CEAs in the oncology literature, including chemoprevention in breast cancer, adjuvant endocrine the

148 ith the model that mesalamine contributes to chemoprevention in CAC by reducing beta-catenin signalin

149 roof-of-concept for a wholly new approach to chemoprevention in carriers of BRCA1 mutations as a stra

150 Chemoprevention in former smokers using the prostacyclin

151 eficial in addition to its potential for HCC chemoprevention in HCV-infected patients.

152 an effective biomarker of CAC or target for chemoprevention in patients with inflammatory bowel dise

153 gement of biliary tract dysplasia and cancer chemoprevention in PSC.

154 The value of chemoprevention in subjects with dysplastic Barrett's es

155 to be done to fully realize the potential of chemoprevention in this disease.

156 rolled in a randomized trial of antimalarial chemoprevention in Tororo, Uganda, an area of high trans

157 an open-label randomized controlled trial of chemoprevention in Ugandan children.

158 ase inhibitors are established breast cancer chemoprevention interventions.

159 ortionately from more intensive screening or chemoprevention interventions.

160 Chemoprevention is a practical and translational approac

161 Prostate cancer chemoprevention is an alternative and potential strategy

162 However, the broad application of chemoprevention is compromised at present by limited eff

163 Chemoprevention is defined as nutritional or pharmaceuti

164 First we agreed that the term chemoprevention is inappropriate and suggested that the

165 If chemoprevention is to be adopted successfully, a holisti

166 lysis indicates that prophylactic surgery or chemoprevention leads to better survival than surveillan

167 ay courses of DP for either seasonal malaria chemoprevention, mass drug administration, or treatment

168 Antimalarial chemoprevention may affect this response by altering exp

169 pothetical uptake) or accepted (real uptake) chemoprevention medications.

170 sents a valuable addition to existing rodent chemoprevention models.

171 r homeostasis, and cancer; new approaches in chemoprevention, molecular diagnostics and genetic testi

172 lled and 393 randomized at 6 mo of age to no chemoprevention, monthly sulfadoxine-pyrimethamine (SP),

173 a global issue, the opportunities offered by chemoprevention must be re-evaluated and uptake of chemo

174 roartemisinin-piperaquine (DP; n = 87) or no chemoprevention (n = 90) from 6 to 24 months of age, wit

175 ems and may lead to novel approaches for the chemoprevention of arsenic toxicity.

176 fene was approved in 2007 by the FDA for the chemoprevention of breast cancer in postmenopausal women

177 n is a widely used drug for chemotherapy and chemoprevention of breast cancer worldwide.

178 natural compound proposed for the treatment/chemoprevention of breast cancer.

179 terpenoid family as effective agents for the chemoprevention of CAC in humans.

180 esis in rat, supporting its potential use in chemoprevention of cancer.

181 metabolites, which are crucial for selenium chemoprevention of cancer.

182 rs may help define this axis as a target for chemoprevention of carcinomas.

183 These results suggest that effective chemoprevention of colon cancer by NSAIDs lies in the el

184 ROS and the mixture may be effective in the chemoprevention of colon cancer.

185 ng as a promising class of compounds for the chemoprevention of colon cancer.

186 eas inhibitors of COX-2 could be of value in chemoprevention of colon cancer.

187 uch as prevention of venous thromboembolism, chemoprevention of colorectal (and other) cancers, and r

188 ory bowel disease, colorectal cancer and the chemoprevention of colorectal adenoma by influencing the

189 ty of GCC hormone replacement therapy in the chemoprevention of colorectal cancer progression.

190 n and signalling represent valid targets for chemoprevention of colorectal cancer.

191 elective COX-2 inhibitors limit their use in chemoprevention of CRC.

192 Chemoprevention of cutaneous melanoma can become a valid

193 ional strategies for risk stratification and chemoprevention of gastric cancer are needed.

194 ion are potent natural dietary compounds for chemoprevention of gastrointestinal cancers.

195 in signaling pathway and may be a target for chemoprevention of HCC.

196 findings may have clinical implications for chemoprevention of hepatocellular carcinoma in the cirrh

197 RATIONALE: Improving the early detection and chemoprevention of lung cancer are key to improving outc

198 otene and Retinol Efficacy Trial (CARET) for chemoprevention of lung cancer, followed prospectively f

199 RET), a study of vitamin supplementation for chemoprevention of lung cancer, has followed 4,060 heavi

200 NF-kappaB pathway as a potential target for chemoprevention of lung cancer.

201 STAT3 is a potential target for chemoprevention of melanoma.

202 , and selection of dose in the treatment and chemoprevention of neurodegenerative disease.

203 ept for regular sunscreen use, the quest for chemoprevention of NMSC in the general population has be

204 Evolving areas include chemoprevention of post-endoscopic retrograde cholangiop

205 Chemoprevention of post-endoscopic retrograde cholangiop

206 This suggests that any potential chemoprevention of prostate cancer by NSAIDs may be most

207 me may be incorporated into regimens for the chemoprevention of skin cancers.

208 y may be an important molecular mechanism in chemoprevention of squamous cell carcinoma by sulforapha

209 In addition, the potential cancer chemoprevention of the secondary metabolites (phenolic e

210 icinal herbs holds exciting promises for the chemoprevention of this disease.

211 at EGFR may be an appropriate target for the chemoprevention of UV-induced skin cancer.

212 Chemoprevention offers a promising strategy for preventi

213 diagnosed at early stages offering a unique chemoprevention opportunity.

214 nsidered for investigation as a strategy for chemoprevention or additional therapy of early HCC in pa

215 is imperative in targeting this pathway for chemoprevention or chemotherapy.

216 o achieve either goal, with seasonal malaria chemoprevention or indoor residual spraying added second

217 ACF that may provide new targets for cancer chemoprevention or lead to the development of new biomar

218 uld help identify women who may benefit from chemoprevention or more screening.

219 t and similar between children randomized to chemoprevention or no chemoprevention.

220 tection of lung cancer and novel targets for chemoprevention or therapy.

221 hese isoforms may be useful in breast cancer chemoprevention or therapy.

222 inflammatory drugs (NSAIDs) are effective in chemoprevention or treatment of cancer.

223 common cancer worldwide that lacks effective chemoprevention or treatment.

224 the subpopulations for which the benefits of chemoprevention outweigh the risks of adverse side-effec

225 a incidence as compared to children given no chemoprevention (P = .004).

226 e risk: 7% with chemoprevention; 21% with no chemoprevention; P < .001).

227 Seasonal malaria chemoprevention, previously known as intermittent preven

228 Chemoprevention provides an opportunity to complement sc

229 itor the efficacy of antiangiogenic drugs or chemoprevention regimens targeting the vasculature in pr

230 urveillance, and identification of effective chemoprevention regimens.

231 ll hopefully streamline head and neck cancer chemoprevention research.

232 nt development are all critical for melanoma chemoprevention research.

233 It is unclear whether chemoprevention similarly enhances immunity following na

234 have reanalyzed 2 trials of seasonal malaria chemoprevention (SMC) in Bousse, Burkina Faso, and Kati,

235 Seasonal Malaria Chemoprevention (SMC) with sulfadoxine-pyrimethamine (SP

236 of action, and the potential for combination chemoprevention strategies that involve tea as well as o

237 er the past 30 years, there are no effective chemoprevention strategies, and only one systemic therap

238 This study aimed at a targeted chemoprevention strategy for BRCA1-associated malignanci

239 ggests that c-Myc inhibition may be a viable chemoprevention strategy for colorectal cancer.

240 investigate the efficacy of a combinatorial chemoprevention strategy for esophageal adenocarcinoma a

241 This chemoprevention strategy has important implications for

242 ims to critically review the potential for a chemoprevention strategy in melanoma, and to discuss new

243 roviding a previously undescribed epigenetic chemoprevention strategy in which cells with LOI are "IG

244 research includes numerous large and smaller chemoprevention studies of nutritional supplements, othe

245 results indicate that COX-2 is an important chemoprevention target and that inhibition of this enzym

246 in TRAMP mice, suggesting NOX as a potential chemoprevention target in controlling PCa.

247 e lysophosphatidic acid pathway as a central chemoprevention target.

248 llowing Apc-loss and constitutes a potential chemoprevention target.

249 ium falciparum sporozoites administered with chemoprevention targeting blood-stage parasites results

250 ay be good for safe and effective metastatic chemoprevention targeting circulating tumor cells (CTC).

251 hat will evaluate the concept of combination chemoprevention targeting COX-2 and EGFR.

252 on factor NF-E2-related factor-2 (NRF2), are chemoprevention targets because of their role in regulat

253 retinal to retinoic acid, could benefit from chemoprevention therapy.

254 fic QOL influence a woman's decision to stop chemoprevention therapy.

255 that in areas suitable for seasonal malaria chemoprevention, there are 39 million children under 5 y

256 ing the rationale for using Nrf2 inducers in chemoprevention, this antioxidative transcription factor

257 Like earlier efforts at chemoprevention, this study failed to show therapeutic b

258 years old) who participated in a prospective chemoprevention trial (of vitamin D and calcium) from 20

259 This large chemoprevention trial did not establish the equivalence

260 ly in Ugandan children enrolled in a malaria chemoprevention trial from 6 to 36 months of age.

261 f CRA in 267 participants of a phase IIb/III chemoprevention trial of DFMO/sulindac.

262 andomized Veterans Affairs Topical Tretinoin Chemoprevention Trial of high-dose topical tretinoin for

263 The Veterans Affairs Keratinocyte Carcinoma Chemoprevention Trial was a randomized clinical trial of

264 -blinded, placebo-controlled 2 x 2 factorial chemoprevention trial was conducted in Linxian, China to

265 tient in the placebo arm of a 4-year primary chemoprevention trial who developed adenomatous polyps a

266 C) in the Veterans Affairs topical tretinoin chemoprevention trial, which included individuals with a

267 g they are ideal candidates for inclusion in chemoprevention trials and require surveillance by perio

268 n data set included participants involved in chemoprevention trials at the British Columbia Cancer Ag

269 Prospective, randomized chemoprevention trials for prostate and other cancers ar

270 Two chemoprevention trials found that supplementation with b

271 e preclinical studies and cardiovascular and chemoprevention trials have raised concerns that high fo

272 tially modifiable intermediate end point for chemoprevention trials in high-risk populations.

273 Chemoprevention trials indicate risk reduction for breas

274 cular attention paid to the results of major chemoprevention trials involving selenium supplementatio

275 d provides an important rationale for future chemoprevention trials of head and neck and lung cancers

276 ividuals for lung cancer in surveillance and chemoprevention trials.

277 ritis and are currently under study in human chemoprevention trials.

278 Patients were drawn from 3 adenoma chemoprevention trials.

279 Breast cancer chemoprevention uptake rates are low and variation is wi

280 Cancer chemoprevention uses natural, synthetic, or biological s

281 taII is an effective target for colon cancer chemoprevention using enzastaurin (LY317615), a PKCbeta-

282 Chemoprevention using nanotechnology to improve the bioa

283 The Veterans Affairs Keratinocyte Carcinoma Chemoprevention (VAKCC) trial was a randomized, double-b

284 ns in the Veterans Affairs Topical Tretinoin Chemoprevention (VATTC) Trial.

285 they have started to be implicated in cancer chemoprevention, via the targeting of reversible epigene

286 In this context, chemoprevention was achieved by using the mammalian targ

287 Chemoprevention was stopped at 24 mo of age, and partici

288 In multivariable analysis, chemoprevention was the only clinical factor associated

289 To explore a molecular mechanism of chemoprevention, we examined the effect of mesalamine on

290 mized controlled trial of colorectal adenoma chemoprevention, we tested whether 1000 IU/day vitamin D

291 ressed patient decisions about breast cancer chemoprevention, were published in 1995 or later, were p

292 ement of severe disease and seasonal malaria chemoprevention where recommended for both Accelerate sc

293 s study represent the experimental basis for chemoprevention with cdk inhibitors in human BE and BAA.

294 ition may be a promising strategy for cancer chemoprevention with lack of the adverse cardiovascular

295 benefit/risk index to quantify benefits from chemoprevention with tamoxifen or raloxifene.

296 feasibility of targeting mPGES-1 for cancer chemoprevention with the potential for improved tolerabi

297 bona fide target for effective combinatorial chemoprevention with Urso and Aspirin.

298 o delay, prevent or reverse carcinogenesis ('chemoprevention') with the ultimate goal of reducing can

299 HuR inhibition as an effective means of FAP chemoprevention, with caution advised in the setting of

300 laria burden in areas where seasonal malaria chemoprevention would be appropriate.